Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | CHKA | P35790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL28843492 | 0.97 | SLC6A4 (0.38) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6960631 | 0.97 | SLC6A4 (0.38) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL11344053 | 0.86 | SLC6A2 (0.35) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL11212725 | 0.86 | SLC6A4 (0.39) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6956663 | 0.84 | SLC6A2 (0.34) | SLC6A4SLC6A2SLC6A3CYP2D6IDO1 | |
| SCHEMBL28252629 | 0.83 | SLC6A4 (0.37) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL14976680 | 0.83 | SIGMAR1 (0.37) | SLC6A4SLC6A2SLC6A3IDO1CHRM5 | |
| SCHEMBL29099885 | 0.80 | SLC6A2 (0.35) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL30842369 | 0.78 | USP2 (0.46) | MEN1KMT2ACYP2D6HSD17B10 | |
| SCHEMBL10537680 | 0.77 | MEN1 (0.34) | SLC6A4SLC6A2SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110229163-B | Method for synthesizing hydroxyalkyl triethylene diamine compound | 嘉兴润博化工科技有限公司 | 2022-05-24 | — | — | CN | claimed |
| CN-104557947-B | A kind of method of 2 methylol triethylene diamines of continuous production | 绍兴兴欣化工有限公司 | 2017-06-27 | — | — | CN | claimed |
| CN-104557947-A | Method of producing 2-hydroxymethyl triethylenediamine continuously | SHAOXING XINGXIN CHEMICAL CO LTD | 2015-04-29 | — | — | CN | claimed |
| EP-3654968-B1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3654968-B1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-110229163-B | Method for synthesizing hydroxyalkyl triethylene diamine compound | 嘉兴润博化工科技有限公司 | 2022-05-24 | — | — | CN | disclosed |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200281913-A1 | Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof | MERCK SHARP & DOHME CORP. (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200281913-A1 | Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof | MERCK SHARP & DOHME CORP. (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3654968-A1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | Merck Sharp & Dohme Corp. (US) | 2020-05-27 | — | — | EP | disclosed |
| WO-2016197009-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-08 | — | — | WO | disclosed |
| CN-104557947-A | Method of producing 2-hydroxymethyl triethylenediamine continuously | SHAOXING XINGXIN CHEMICAL CO LTD | 2015-04-29 | — | — | CN | disclosed |
| CN-104557947-A | Method of producing 2-hydroxymethyl triethylenediamine continuously | SHAOXING XINGXIN CHEMICAL CO LTD | 2015-04-29 | — | — | CN | disclosed |
| EP-2295438-B1 | PROCESS FOR PRODUCING HYDROXYALKYLTRIETHYLENEDIAMINE COMPOUND, AND CATALYST COMPOSITION FOR THE PRODUCTION OF POLYURETHANE RESIN USING THE HYDROXYALKYLTRIETHYLENEDIAMINE COMPOUND | TOSOH CORP (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-20110077376-A1 | PROCESS FOR PRODUCING HYDROXYALKYLTRIETHYLENEDIAMINE, AND CATALYST COMPOSITION FOR THE PRODUCTION OF POLYURETHANE RESIN USING IT | TOSOH CORPORATION (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20110077376-A1 | PROCESS FOR PRODUCING HYDROXYALKYLTRIETHYLENEDIAMINE, AND CATALYST COMPOSITION FOR THE PRODUCTION OF POLYURETHANE RESIN USING IT | TOSOH CORPORATION (JP) | 2011-03-31 | — | — | US | disclosed |
| EP-2295438-A1 | PROCESS FOR PRODUCING HYDROXYALKYLTRIETHYLENEDIAMINE COMPOUND, AND CATALYST COMPOSITION FOR THE PRODUCTION OF POLYURETHANE RESIN USING THE HYDROXYALKYLTRIETHYLENEDIAMINE COMPOUND | Tosoh Corporation (JP) | 2011-03-16 | — | — | EP | disclosed |
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200281913-A1 | Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof | MLX, MMP12, SLC11A2 | SLC6A4 2162/4885SLC6A2 856/4885SLC6A3 1263/4885 |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | SLC6A4 2697/4885SLC6A2 3204/4885SLC6A3 3889/4885 |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MLX, MMP12, SLC11A2 | SLC6A4 2162/4885SLC6A2 856/4885SLC6A3 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.